| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to compounds of formula I, where R 1 is or phenyl, pyridinyl or pyridazinyl, where phenyl, pyridinyl, pyridazinyl can be substituted with cyano, lower alkyl, halogen-substituted phenyl, lower alkyl-substituted [1,2,4]oxadiazol-3-yl or 2-oxo-piperidin-1-yl, X is NR or O, R is -C(O)-lower alkyl, -C(O)-cycloalkyl substituted with lower alkyl, cycloalkyl or phenyl, pyridinyl or pyridazinyl, where phenyl, pyridinyl, pyridazinyl can be substituted with lower alkyl, lower alkoxy, cyano, -C(O)-lower alkyl, halogen or lower alkyl, substituted with halogen, R 2 represents hydrogen or lower alkyl, R 3 represents hydrogen, halogen, R 4 is hydrogen or lower alkyl, where R 2 and R 4 simultaneously are not hydrogen or lower alkyl, R 5 denotes lower alkyl, R 6 - halogen, or their pharmaceutically acceptable acid-additive salts. n EFFECT: it has been found that present compounds are high potential NK-3 receptor antagonists for treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). n 18 cl, 36 ex |